BMS and Eisai to collaborate in deal worth up to $3.1bn

The drug is currently in development in two studies – a phase 1 clinical study in Japan and a phase 1/2 study in the US.

How early-stage clinical research is facilitating the new wave of personalised medicines

is also being used to treat autoimmune and cardiac conditions, and biologic medicines, which now account for 15% of medicines prescribed in Japan and 30% in the USA (in 2018).

Novo Nordisk partners with Heartseed on heart failure cell therapy

However, Novo Nordisk has the rights to co-commercialise HS-001 with Heartseed in Japan, with equal profit and cost sharing. ... The Japanese biotech company is also eligible to receive tiered high single-digit to low double-digit royalties of annual net

BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer

As part of that agreement, Novartis gained development and commercialisation rights to tislelizumab in the US, Canada, Mexico, the EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan for an upfront

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]